Recent developments on future antidepressant-related serotonin receptors

Meysam Amidfar, Yong Ku Kim

Research output: Contribution to journalReview article

2 Citations (Scopus)

Abstract

Conventional serotonin-enhancing antidepressants including selective serotonin reuptake inhibitors (SSRIs) and serotonin and norepinephrine reuptake inhibitors (SNRIs) have shown effectiveness in the treatment of major depression, but their significant limitations such as slowness of action have led to intensive research efforts to develop new antidepressants. Increased synaptic neurotransmission of serotonin (5-hdroxytryptamine; 5-HT) through orchestration of stimulation and blockade of various subtypes of 5-HT receptors is involved in the mechanisms of action of SSRIs. Agonists at the 5-HT1A, 5-HT1B, 5-HT2C, 5-HT4, and 5-HT6 receptors and antagonists at the 5-HT1A, 5-HT2A, 5-HT2C, 5-HT3, 5-HT6, and 5-HT7 receptors have shown antidepressant properties in clinical and preclinical studies. However, paradoxical antidepressant-like effects of both agonists and antagonists at particular 5-HT receptors suggest the need to consider the neurochemical mechanisms of each 5-HT receptor subtype. Therefore, better knowledge of the involvement of individual 5-HT receptors in the mechanisms of action of currently used antidepressants as well as antidepressant effects of selective ligands of 5-HT receptor subtypes will provide opportunities for the development of future antidepressants with more rapid onset of action, fewer side effects, and better efficacy than SSRIs.

Original languageEnglish
Pages (from-to)2541-2548
Number of pages8
JournalCurrent Pharmaceutical Design
Volume24
Issue number22
DOIs
Publication statusPublished - 2018 Jan 1

Fingerprint

Serotonin Receptors
Antidepressive Agents
Serotonin Uptake Inhibitors
Serotonin
Serotonin 5-HT4 Receptor Antagonists
Serotonin 5-HT1 Receptor Agonists
Synaptic Transmission
Ligands
Research

Keywords

  • Antidepressant
  • Depression
  • Selective serotonin reuptake inhibitors
  • Serotonin
  • Ssri
  • Synaptic neurotransmission of serotonin

ASJC Scopus subject areas

  • Pharmacology
  • Drug Discovery

Cite this

Recent developments on future antidepressant-related serotonin receptors. / Amidfar, Meysam; Kim, Yong Ku.

In: Current Pharmaceutical Design, Vol. 24, No. 22, 01.01.2018, p. 2541-2548.

Research output: Contribution to journalReview article

@article{09e48f63d92140139a3c18458f631c6a,
title = "Recent developments on future antidepressant-related serotonin receptors",
abstract = "Conventional serotonin-enhancing antidepressants including selective serotonin reuptake inhibitors (SSRIs) and serotonin and norepinephrine reuptake inhibitors (SNRIs) have shown effectiveness in the treatment of major depression, but their significant limitations such as slowness of action have led to intensive research efforts to develop new antidepressants. Increased synaptic neurotransmission of serotonin (5-hdroxytryptamine; 5-HT) through orchestration of stimulation and blockade of various subtypes of 5-HT receptors is involved in the mechanisms of action of SSRIs. Agonists at the 5-HT1A, 5-HT1B, 5-HT2C, 5-HT4, and 5-HT6 receptors and antagonists at the 5-HT1A, 5-HT2A, 5-HT2C, 5-HT3, 5-HT6, and 5-HT7 receptors have shown antidepressant properties in clinical and preclinical studies. However, paradoxical antidepressant-like effects of both agonists and antagonists at particular 5-HT receptors suggest the need to consider the neurochemical mechanisms of each 5-HT receptor subtype. Therefore, better knowledge of the involvement of individual 5-HT receptors in the mechanisms of action of currently used antidepressants as well as antidepressant effects of selective ligands of 5-HT receptor subtypes will provide opportunities for the development of future antidepressants with more rapid onset of action, fewer side effects, and better efficacy than SSRIs.",
keywords = "Antidepressant, Depression, Selective serotonin reuptake inhibitors, Serotonin, Ssri, Synaptic neurotransmission of serotonin",
author = "Meysam Amidfar and Kim, {Yong Ku}",
year = "2018",
month = "1",
day = "1",
doi = "10.2174/1381612824666180803111240",
language = "English",
volume = "24",
pages = "2541--2548",
journal = "Current Pharmaceutical Design",
issn = "1381-6128",
publisher = "Bentham Science Publishers B.V.",
number = "22",

}

TY - JOUR

T1 - Recent developments on future antidepressant-related serotonin receptors

AU - Amidfar, Meysam

AU - Kim, Yong Ku

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Conventional serotonin-enhancing antidepressants including selective serotonin reuptake inhibitors (SSRIs) and serotonin and norepinephrine reuptake inhibitors (SNRIs) have shown effectiveness in the treatment of major depression, but their significant limitations such as slowness of action have led to intensive research efforts to develop new antidepressants. Increased synaptic neurotransmission of serotonin (5-hdroxytryptamine; 5-HT) through orchestration of stimulation and blockade of various subtypes of 5-HT receptors is involved in the mechanisms of action of SSRIs. Agonists at the 5-HT1A, 5-HT1B, 5-HT2C, 5-HT4, and 5-HT6 receptors and antagonists at the 5-HT1A, 5-HT2A, 5-HT2C, 5-HT3, 5-HT6, and 5-HT7 receptors have shown antidepressant properties in clinical and preclinical studies. However, paradoxical antidepressant-like effects of both agonists and antagonists at particular 5-HT receptors suggest the need to consider the neurochemical mechanisms of each 5-HT receptor subtype. Therefore, better knowledge of the involvement of individual 5-HT receptors in the mechanisms of action of currently used antidepressants as well as antidepressant effects of selective ligands of 5-HT receptor subtypes will provide opportunities for the development of future antidepressants with more rapid onset of action, fewer side effects, and better efficacy than SSRIs.

AB - Conventional serotonin-enhancing antidepressants including selective serotonin reuptake inhibitors (SSRIs) and serotonin and norepinephrine reuptake inhibitors (SNRIs) have shown effectiveness in the treatment of major depression, but their significant limitations such as slowness of action have led to intensive research efforts to develop new antidepressants. Increased synaptic neurotransmission of serotonin (5-hdroxytryptamine; 5-HT) through orchestration of stimulation and blockade of various subtypes of 5-HT receptors is involved in the mechanisms of action of SSRIs. Agonists at the 5-HT1A, 5-HT1B, 5-HT2C, 5-HT4, and 5-HT6 receptors and antagonists at the 5-HT1A, 5-HT2A, 5-HT2C, 5-HT3, 5-HT6, and 5-HT7 receptors have shown antidepressant properties in clinical and preclinical studies. However, paradoxical antidepressant-like effects of both agonists and antagonists at particular 5-HT receptors suggest the need to consider the neurochemical mechanisms of each 5-HT receptor subtype. Therefore, better knowledge of the involvement of individual 5-HT receptors in the mechanisms of action of currently used antidepressants as well as antidepressant effects of selective ligands of 5-HT receptor subtypes will provide opportunities for the development of future antidepressants with more rapid onset of action, fewer side effects, and better efficacy than SSRIs.

KW - Antidepressant

KW - Depression

KW - Selective serotonin reuptake inhibitors

KW - Serotonin

KW - Ssri

KW - Synaptic neurotransmission of serotonin

UR - http://www.scopus.com/inward/record.url?scp=85055497166&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85055497166&partnerID=8YFLogxK

U2 - 10.2174/1381612824666180803111240

DO - 10.2174/1381612824666180803111240

M3 - Review article

C2 - 30073919

AN - SCOPUS:85055497166

VL - 24

SP - 2541

EP - 2548

JO - Current Pharmaceutical Design

JF - Current Pharmaceutical Design

SN - 1381-6128

IS - 22

ER -